Home HOME Neoplasma 2020 Neoplasma Vol.67, No.5, p.1139–1145, 2020

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.67, No.5, p.1139–1145, 2020

Title: Decreased expression of GBA3 correlates with a poor prognosis in hepatocellular carcinoma patients
Author: J. F. Ying, Y. N. Zhang, S. S. Song, Z. M. Hu, X. L. He, H. Y. Pan, C. W. Zhang, H. J. Wang, W. F. Li, X. Z. Mou

Abstract: Beta-glucosidase (GBA), also known as acid β-glucosidase, exhibits an activity of glucosylceramidase (EC Three main isoforms of β-glucosidases have been identified in mammals: GBA1, GBA2, and GBA3. The deficiency of these enzymes leads to glucosylceramide accumulation, resulting in Gaucher’s disease. The present study is focused on the cytosolic β-glucosidase, GBA3, and its relationship with hepatocellular carcinoma (HCC). The expression of GBA3 mRNA in HCC was evaluated first using the TCGA database, and then by immunohistochemistry using tissue microarrays of 328 clinically characterized HCC samples and 151 non-tumor liver controls. Moreover, the presence of a correlation between GBA3 expression and clinicopathological characteristics of patients was examined. The obtained results indicated that the expression of GBA3 mRNA was significantly lower in HCC than in the adjacent non-tumor liver tissues. The expression of GBA3 was inversely related to the number of tumors (p=0.041), tumor size (p

Keywords: glucosidase, hepatocellular carcinoma, immunohistochemistry, bioinformatics
Published online: 14-May-2020
Year: 2020, Volume: 67, Issue: 5 Page From: 1139, Page To: 1145

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.